Mirococept API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Mirococept API 507453-82-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Mirococept. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Mirococept
- Synonyms:
- myristoylated recombinant SCR1-3 of human complement reseptor type I
- Cas Number:
- 507453-82-9
- DrugBank number:
- DB06492
- Unique Ingredient Identifier:
- FX636ZF1CI
General Description:
Mirococept, identified by CAS number 507453-82-9, is a notable compound with significant therapeutic applications. Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation. It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the naturally occurring membrane-bound myristoyl-electrostatic switch peptide.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in transplant (rejection), kidney disease, and rheumatoid arthritis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Mirococept functions by: Mirococept comprises the C3/C5 convertase-inhibiting region of CR1. This complement inhibitory domains of CR1 (in APT070) contain C3b-binding sites that lead to dissociation and inactivation of C3b from the classical and alternative pathway convertases. Mirococept effectively blocks and reduces the generation of the activated form of C3, and thwarts the release of both C3a and C5a. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Mirococept belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Mirococept is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
